Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | CDRH A-Z Index | Contact CDRH U.S. Food and Drug Administration Center for Devices and Radiological Health
horizonal rule

Consumer (CDRH/FDA) (Consumer Photo Montage)
Skip Consumer NavigationConsumer Home Product Information Choosing a Medical Device How We Can Help Resources Problems with Medical Devices

(See Related Information)
New Device Approval

CosmoDerm™ 1 Human-Based Collagen, CosmoDerm™ 2 Human-Based Collagen and CosmoPlast™ Human-Based Collagen - P800022/S050

This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness and product labeling for more complete information on this product, its indications for use, and the basis for FDA's approval.


Product Name: CosmoDerm™ 1 Human-Based Collagen, CosmoDerm™ 2 Human-Based Collagen CosmoPlast™ Human-Based Collagen
Manufacturer:
INAMED Corporation
Address:
5540 Ekwill Street, Santa Barbara, CA 93111 USA
Approval Date:
March 11, 2003
Approval Letter: 
http://www.fda.gov/cdrh/pdf3/p800022s050a.pdf

What is it? CosmoDerm and CosmoPlast Human-Based Collagen implants are sterile injectable liquids made of highly purified human collagen, a natural protein that supports the skin. They’re injected into the skin to correct soft tissue defects such as wrinkles and acne scars. These products also contain lidocaine, which numbs the skin at the site of injection.
CosmoDerm is used for minor skin defects. CosmoPlast is used for more serious defects.

When is it used? To correct soft tissue contour defects, such as wrinkles and acne scars.

What will it accomplish? Previous studies with injections of collagen derived from cows showed that collagen injections can fill soft tissue contour defects. Clinical studies of injections with human collagen showed that the frequency of adverse immune responses (rejection by the body) with the use of CosmoDerm™ 1 Human-Based Collagen is less than 1.3%. Because of the low percent of adverse responses, each of these two products may be injected without a skin test prior to treatment.

When should it not be used?

Additional information:

Other:

Updated 5/12/2003

horizonal rule

CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

Center for Devices and Radiological Health / CDRH